To investigate the role of WNK1 in acute myeloid leukemia (AML) and evaluate the effects of its inhibition on AML progression and responsiveness to venetoclax.
Key Findings:
WNK1 is highly expressed in AML, particularly in adverse subtypes like FLT3-ITD mutated AML.
WNK1 is essential for AML cell survival as confirmed by CRISPR screening.
Pharmacological inhibition of WNK1 suppressed AML cell proliferation and induced apoptosis.
WNK1 inhibition downregulated DNA replication pathway genes associated with poor prognosis.
Elevated WNK1 expression correlated with resistance to venetoclax.
Combining WNK463 with venetoclax resulted in synergistic anti-leukemic effects.
Interpretation:
Limitations:
The study primarily focuses on in vitro and xenograft models, which may not fully replicate human AML complexity.
Further clinical studies are needed to validate the findings and assess the safety and efficacy of WNK1 inhibitors in patients.
